The Small Fiber Neuropathy Network
We have the nerve to fight back!
📚 Evidence-Based Information: All medical content on this website is backed by peer-reviewed journals, systematic reviews, clinical trials, and reputable medical organizations. We carefully summarize, paraphrase, and reference only credible scientific literature from leading medical institutions. View our comprehensive sources page with 70+ citations from top-tier medical journals. Spotted any discrepancies or questionable sources? We'd love to hear from you.

Current Research in Small Fiber Neuropathy

Latest developments, clinical trials, and future directions in SFN research

🔬 Research Highlights

SFN research is rapidly advancing with new diagnostic tools, treatments, and understanding of disease mechanisms.

🧬 Genetic Research

Scientists are identifying genetic mutations associated with inherited forms of SFN, including:

  • Sodium channel mutations (SCN9A, SCN10A, SCN11A)
  • TRPA1 channel dysfunction
  • Mitochondrial DNA variants
  • Immune system gene variations

🎯 New Drug Targets

Researchers are developing medications targeting specific mechanisms:

  • Nerve growth factor (NGF) modulators
  • TRPV1 receptor antagonists
  • Neuroinflammation pathways
  • Mitochondrial protection compounds

🏥 Diagnostic Advances

New methods for earlier and more accurate diagnosis:

  • Corneal confocal microscopy improvements
  • Advanced quantitative sensory testing
  • Biomarker development
  • AI-assisted skin biopsy analysis

🌱 Regenerative Medicine

Exploring ways to repair or regrow damaged nerve fibers:

  • Stem cell therapy trials
  • Gene therapy approaches
  • Growth factor treatments
  • Tissue engineering methods

🧪 Active Clinical Trials

Here are notable, currently listed clinical trials relevant to SFN. For the complete and up-to-date record, see our Trials page.

IVIG for Autoimmune Small Fiber Neuropathy (NCT04153422)

Status: Recruiting • Location: Evanston, Illinois (Endeavor Health)

  • Randomized, double-blind, placebo-controlled Phase II
  • Primary outcome: Change in intraepidermal nerve fiber density after 6 months
  • Secondary outcomes: Pain reduction and disability improvement

View on ClinicalTrials.gov

SFN Research Study (NCT06287736)

See official record for current status and eligibility.

View on ClinicalTrials.gov

SFN Research Study (NCT06980948)

See official record for current status and details.

View on ClinicalTrials.gov